Insider Selling: BioNTech (NASDAQ:BNTX) CEO Sells 30,000 Shares of Company Stock

BioNTech SE Sponsored ADR (NASDAQ:BNTX) CEO Ugur Sahin sold 30,000 shares of BioNTech stock in a transaction on Wednesday, September 23rd. The stock was sold at an average price of $99.40, for a total transaction of $2,982,000.00. Following the transaction, the chief executive officer directly owned 380,209 shares of the company’s stock, valued at $37,792,774.60. The trade was a 7.31% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ugur Sahin also recently made the following trade(s):

• On Thursday, September 24th, Ugur Sahin sold 39,000 shares of BioNTech stock. The shares were sold at an average price of $98.99, for a total transaction of $3,860,610.00.
• On Tuesday, September 22nd, Ugur Sahin sold 46,000 shares of BioNTech stock. The stock was sold at an average price of $100.72, for a total transaction of $4,633,120.00.
• On Monday, September 21st, Ugur Sahin sold 33,000 shares of BioNTech stock. The stock was sold at an average price of $97.81, for a total transaction of $3,227,730.00.
• On Friday, September 18th, Ugur Sahin sold 30,000 shares of BioNTech stock. The shares were sold at an average price of $96.22, for a total transaction of $2,886,600.00.
• On Thursday, September 17th, Ugur Sahin sold 34,000 shares of BioNTech stock. The shares were sold at an average price of $98.60, for a total transaction of $3,352,400.00.
• On Wednesday, September 16th, Ugur Sahin sold 15,000 shares of BioNTech stock. The stock was sold at an average price of $96.09, for a total transaction of $1,441,350.00.
• On Tuesday, September 15th, Ugur Sahin sold 34,000 shares of BioNTech stock. The stock was sold at an average price of $96.49, for a total transaction of $3,280,660.00.
• On Monday, September 14th, Ugur Sahin sold 41,000 shares of BioNTech stock. The shares were sold at an average price of $99.45, for a total value of $4,077,450.00.
• On Friday, September 11th, Ugur Sahin sold 45,000 shares of BioNTech stock. The shares were sold at an average price of $96.93, for a total value of $4,361,850.00.
• On Thursday, September 10th, Ugur Sahin sold 20,500 shares of BioNTech stock. The stock was sold at an average price of $96.31, for a total value of $1,974,355.00.

BioNTech Trading Up 0.8%

Shares of NASDAQ:BNTX traded up $0.80 on Thursday, hitting $99.26. 787,100 shares of the company’s stock were exchanged, compared to its average volume of 1,098,895. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.85 and a quick ratio of 7.80. The stock has a market capitalization of $25.10 billion, a price-to-earnings ratio of -12.68 and a beta of 1.29. The business’s 50 day simple moving average is $97.88 and its two-hundred day simple moving average is $94.78. BioNTech SE Sponsored ADR has a 12 month low of $79.52 and a 12 month high of $124.00.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($2.53) EPS for the quarter, missing the consensus estimate of ($2.40) by ($0.13). BioNTech had a negative return on equity of 6.86% and a negative net margin of 63.54%.The firm had revenue of $122.31 million for the quarter, compared to analysts’ expectations of $180.18 million. During the same quarter in the previous year, the business earned ($1.60) earnings per share. The company’s revenue for the quarter was down 59.5% compared to the same quarter last year. Analysts anticipate that BioNTech SE Sponsored ADR will post -6.37 EPS for the current fiscal year.

Hedge Funds Weigh In On BioNTech

Several large investors have recently bought and sold shares of BNTX. Larson Financial Group LLC increased its position in BioNTech by 86.4% in the fourth quarter. Larson Financial Group LLC now owns 274 shares of the company’s stock worth $26,000 after buying an additional 127 shares during the period. AlphaCentric Advisors LLC boosted its holdings in shares of BioNTech by 5.7% during the first quarter. AlphaCentric Advisors LLC now owns 5,616 shares of the company’s stock valued at $499,000 after acquiring an additional 305 shares during the period. USS Investment Management Ltd grew its position in shares of BioNTech by 1.2% during the first quarter. USS Investment Management Ltd now owns 32,577 shares of the company’s stock worth $2,854,000 after acquiring an additional 382 shares during the last quarter. Integrated Wealth Concepts LLC bought a new position in shares of BioNTech during the second quarter worth about $39,000. Finally, Marks Group Wealth Management Inc increased its holdings in shares of BioNTech by 16.0% in the 1st quarter. Marks Group Wealth Management Inc now owns 3,454 shares of the company’s stock worth $307,000 after acquiring an additional 476 shares during the period. Institutional investors and hedge funds own 15.52% of the company’s stock.

Analysts Set New Price Targets

BNTX has been the topic of several recent research reports. Jefferies Financial Group reissued a “buy” rating on shares of BioNTech in a research report on Monday, June 1st. Sanford C. Bernstein reiterated a “market perform” rating on shares of BioNTech in a report on Friday, June 5th. Weiss Ratings reiterated a “sell (d-)” rating on shares of BioNTech in a report on Monday, July 6th. UBS Group reiterated a “buy” rating on shares of BioNTech in a research note on Wednesday, September 16th. Finally, Citigroup lowered their target price on shares of BioNTech from $130.00 to $125.00 and set a “buy” rating for the company in a research note on Wednesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, five have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $126.00.

BioNTech Company Profile

BioNTech SE is a biotechnology company focused on developing immunotherapies and vaccines for cancer and other serious diseases. Its research platforms include messenger RNA, cell therapies, protein-based therapeutics, antibody therapies and small-molecule immunomodulators.

The company is best known for Comirnaty, its COVID-19 vaccine developed and commercialized globally in collaboration with Pfizer. BioNTech is also advancing a broad oncology pipeline that includes individualized and off-the-shelf cancer vaccines, antibody-based treatments, cell therapies and combination approaches designed to stimulate or direct the immune system against tumors.

BioNTech was founded in 2008 and is headquartered in Mainz, Germany.